Literature DB >> 15192120

Human tissue kallikreins: physiologic roles and applications in cancer.

Carla A Borgoño1, Iacovos P Michael, Eleftherios P Diamandis.   

Abstract

Tissue kallikreins are members of the S1 family (clan SA) of trypsin-like serine proteases and are present in at least six mammalian orders. In humans, tissue kallikreins (hK) are encoded by 15 structurally similar, steroid hormone-regulated genes (KLK) that colocalize to chromosome 19q13.4, representing the largest cluster of contiguous protease genes in the entire genome. hKs are widely expressed in diverse tissues and implicated in a range of normal physiologic functions from the regulation of blood pressure and electrolyte balance to tissue remodeling, prohormone processing, neural plasticity, and skin desquamation. Several lines of evidence suggest that hKs may be involved in cascade reactions and that cross-talk may exist with proteases of other catalytic classes. The proteolytic activity of hKs is regulated in several ways including zymogen activation, endogenous inhibitors, such as serpins, and via internal (auto)cleavage leading to inactivation. Dysregulated hK expression is associated with multiple diseases, primarily cancer. As a consequence, many kallikreins, in addition to hK3/PSA, have been identified as promising diagnostic and/or prognostic biomarkers for several cancer types, including ovarian, breast, and prostate. Recent data also suggest that hKs may be causally involved in carcinogenesis, particularly in tumor metastasis and invasion, and, thus, may represent attractive drug targets to consider for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192120

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  75 in total

1.  Expression of kallikrein, bradykinin b2 receptor, and endothelial nitric oxide synthase in placenta in normal gestation, preeclampsia, and placenta accreta.

Authors:  Jenny Corthorn; Alfredo A Germain; Cecilia Chacón; Sergio Rey; Gloria X Soto; Carlos D Figueroa; Werner Müller-Esterl; Ignacio Duarte; Gloria Valdés
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

2.  Comparative sequence analyses reveal rapid and divergent evolutionary changes of the WFDC locus in the primate lineage.

Authors:  Belen Hurle; Willie Swanson; Eric D Green
Journal:  Genome Res       Date:  2007-01-31       Impact factor: 9.043

3.  Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin.

Authors:  Prodipto Pal; Huifeng Xi; Guangyun Sun; Ritesh Kaushal; Joshua J Meeks; C Shad Thaxton; Saurav Guha; Carol H Jin; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Hum Genet       Date:  2007-06-26       Impact factor: 4.132

4.  Substrate specificity of human kallikreins 1 and 6 determined by phage display.

Authors:  Hai-Xin Li; Bum-Yeol Hwang; Gurunathan Laxmikanthan; Sachiko I Blaber; Michael Blaber; Pavel A Golubkov; Pengyu Ren; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

Review 5.  The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease.

Authors:  I A Scarisbrick
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

Review 6.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

7.  Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.

Authors:  Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Elisabet Cuyàs; Bruna Corominas-Faja; Esther Rodríguez-Gallego; Salvador Fernández-Arroyo; Begoña Martin-Castillo; Jorge Joven; Javier A Menendez
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

8.  The canine kallikrein-related peptidases 9 and 10: structural characterization and expression in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2009-12-02       Impact factor: 2.957

Review 9.  Tumour endoproteases: the cutting edge of cancer drug delivery?

Authors:  J M Atkinson; C S Siller; J H Gill
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

10.  Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.

Authors:  Valérie Gratio; Nathalie Beaufort; Lina Seiz; Josefine Maier; G Duke Virca; Mekdes Debela; Nicolai Grebenchtchikov; Viktor Magdolen; Dalila Darmoul
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.